Abstract:Background The imbalance of T help 17 cells (Th17)/regulatory T cells (Tregs) is considered to be a pivotal cause of autoimmune diseases1, including systemic lupus erythematosus (SLE). However, previous reports1,2 describing the respective changes of Tregs and Th17 cells in SLE patients were controversial because a few samples or diverse markers were used to identify Tregs with little consensus. Objectives To clarify the status of Tregs and Th17 in SLE, we investigated the frequencies of Tregs and Th17 cells on a large scale and whether those defects can be corrected by the supplementation of low-dose human recombinant interleukin-2 (IL-2). Methods Two hundred and thirty-five SLE patients (219 women and 16 men), with mean age of 37.80±14.00 years, were enrolled. The disease activity using European League Against Rheumatism (EULAR) criteria was judged for SLE patients with erythrocyte sedimentation rate (ESR) and SLEDAI scores. The frequencies of CD3+CD4+FOXP3+Treg cells and Th17 cells in peripheral blood from these patients were measured by flow cytometry. And low-dose IL-2 was used among 127 patients at a dosage of fifty WIU every day for five days. Immunological and clinical assessments were performed again at the end of IL-2 treatment. Ninety healthy volunteers, matched for patients9 age and gender, were also included for the estimation of CD4+ T cell subsets. Results As compared to healthy controls (median of Treg cells: 33.09 cells/ul), the frequencies of circulating CD4+CD25+FOXP3+Treg cells were significantly decreased in SLE patients (median: 15.49 cells/ul, P<0.001). The median ratios of Th17/Tregs cells in patients were greatly higher than those of healthy volunteers [0.42 (0.19, 0.88) vs. 0.21 (0.15, 0.34), P<0.001]. There was not significantly different in circulating Th17 cell between two groups. Moreover, CD4+CD25+FOXP3+Treg cells were negatively correlated with ESR and SLEDAI score (r=-0.198, P=0.01; r=-0.25, P=0.002).While no obvious correlation was seen between Th17 cells and SLEDAI score. After IL-2 therapy in SLE, there was a four-fold increase in circulating CD4+CD25+FOXP3+Treg cells [43.73 (24.08,74.22) vs. 11.95 (7.51,20.34),P<0.001], whereas Th17 cells were increased slightly. The ratio of Th17/Tregs was decreased significantly in patients with IL-2 treatment [0.19 (0.09,0.41) vs. 0.52 (0.23,0.95),P<0.001], tended to balance and had no difference with healthy individual (P=0.275). Conclusions With the increase of disease activity,CD4+CD25+FOXP3+Treg cells were gradually reducing, while Th17 cells did not show a significant change, indicating that the reduction of Tregs but not the elevation of Th17 cells may be the major reason for imbalance of Th17/Tregs. It is speculated that SLE is an autoimmune disease triggered by the defect of immunotolerance. More importantly, low-dose IL-2 selectively modulated the abundance of Tregs, which effectively induced autoimmune tolerance and further improved clinical symptoms. References Ji Y, Xue Y, Hejian Z, et al.Recovery of the immune balance betweenTh17 and regulatory T cells as a treatment for systemic lupus erythematosus[J]. Rheumatology 2011;50:1366–1372. Steinmetz OM, Turner JE, Paust HJ et al. CXCR3 mediates renal Th1 and Th17 immune response in murine lupus nephritis[J]. J Immunol 2009;183:4693–704. Disclosure of Interest None declared

Impact of climate factors and climate–gene interaction on systemic lupus erythematosus patients' response to glucocorticoids therapy

Dysregulated T Cell Activation and Aberrant Cytokine Expression Profile in Systemic Lupus Erythematosus.

Hsp70 Gene Polymorphisms Are Associated With Disease Susceptibility and HRQOL Improvement in Chinese Han Population With Systemic Lupus Erythematosus

Molecular mechanisms of glucocorticoid resistance in systemic lupus erythematosus: A review

OP0043 the Number of Circulating Regulatory T Cells is Reduced and Low-Dose Il-2 Selectively Stimulates Its Proliferation in Patients with Systemic Lupus Erythematosus

FRI0450 Associations of alterations of peripheral regulatory t and th17 absolute cell numbers with clinical features in patients with systemic sclerosis

Real-world treatment patterns in patients with systemic lupus erythematosus: associations with comorbidities and damage

Flare Rates and Factors Determining Flare Occurrence in Patients with Systemic Lupus Erythematosus Who Achieved Low Disease Activity or Remission: Results from a Prospective Cohort Study

Associations of RPEL1 and miR-1307 gene polymorphisms with disease susceptibility, glucocorticoid efficacy, anxiety, depression, and health-related quality of life in Chinese systemic lupus erythematosus patients

[Interactions Between Susceptible Genes and Risk Environmental Factors in Chinese Females with Systemic Lupus Erythematosus].

Genetic susceptibility and clinical features of CYP2D6 associated with systemic lupus erythematosus in a Chinese population

Gene-gene Interaction of BLK, TNFSF4, TRAF1, TNFAIP3, and REL in Systemic Lupus Erythematosus.

Gut microbiota regulation of T lymphocyte subsets during systemic lupus erythematosus

Deciphering cell-specific genetic insights: Unraveling the immunogenetic landscape of systemic lupus erythematosus

Identification of potential therapeutic targets for systemic lupus erythematosus based on GEO database analysis and Mendelian randomization analysis

Association Between Gamma-Glutamyl Transferase, Total Bilirubin and Systemic Lupus Erythematosus in Chinese Women

Use of Glucocorticoids in SLE: A Clinical Approach

Therapeutic Responses and Predictors of Low-Dose Interleukin-2 in Systemic Lupus Erythematosus.

Polygenic risk score: the potential role in the management of systemic lupus erythematosus

Imbalance of Th17 cells, Treg cells and associated cytokines in patients with systemic lupus erythematosus: a meta-analysis

Effects Of Glucocorticoiids On Expression Of Cd4+ Foxp(3+) T Cell In Patients With Systemic Lupus Erythematosus